The quantification of residual plasmatic ADAMTS13 activity in congenital thrombotic thrombocytopenic purpura (TTP) patients is constrained by limitations in sensitivity and reproducibility of commonly used assays at low levels of ADAMTS13 activity, blunting efforts to establish genotype-phenotype correlations. In this study, the residual plasmatic activity of ADAMTS13 was centrally measured by SELDI-TOF mass spectrometry (limit-of-detection=0.5%) in 29 congenital TTP patients. The results were used to study correlations between ADAMTS13 genotype, residual plasmatic activity and clinical phenotype severity. An ADAMTS13 activity above 0.5% was measured in 26 (90%) patients and lower levels of activity were associated with earlier age at first TTP episode requiring plasma infusion, more frequent recurrences and prescription of fresh frozen plasma prophylaxis. At receiver operating characteristic curve analysis, activity levels of less than 2.74% and 1.61% were discriminative of age at first TTP episode requiring plasma infusion <18 years, annual rate of TTP episodes >1, and use of prophylaxis. Mutations affecting the highly-conserved N-terminal domains of the protein were associated with lower residual ADAMTS13 activity and more severe phenotype in an allelic-dose dependent manner. Our results show that residual ADAMTS13 activity correlates with the severity of clinical phenotype in congenital TTP and provide insights into genotype-phenotype correlations.
Residual plasmatic activity of ADAMTS13 correlates with phenotype severity in congenital thrombotic thrombocytopenic purpura / L.A. Lotta, H.M. Wu, I.J. Mackie, M. Noris, A. Veyradier, M.A. Scully, G. Remuzzi, P. Coppo, R. Lisner, R. Donadelli, C. Loirat, R.A. Gibbs, A. Horne, S. Yang, I.M. Garagiola, K.M. Musallam, F. Peyvandi. - In: BLOOD. - ISSN 0006-4971. - 120:2(2012 Jul 12), pp. 440-448. [10.1182/blood-2012-01-403113]
Residual plasmatic activity of ADAMTS13 correlates with phenotype severity in congenital thrombotic thrombocytopenic purpura
L.A. Lotta
;G. Remuzzi;I.M. Garagiola;F. PeyvandiUltimo
2012
Abstract
The quantification of residual plasmatic ADAMTS13 activity in congenital thrombotic thrombocytopenic purpura (TTP) patients is constrained by limitations in sensitivity and reproducibility of commonly used assays at low levels of ADAMTS13 activity, blunting efforts to establish genotype-phenotype correlations. In this study, the residual plasmatic activity of ADAMTS13 was centrally measured by SELDI-TOF mass spectrometry (limit-of-detection=0.5%) in 29 congenital TTP patients. The results were used to study correlations between ADAMTS13 genotype, residual plasmatic activity and clinical phenotype severity. An ADAMTS13 activity above 0.5% was measured in 26 (90%) patients and lower levels of activity were associated with earlier age at first TTP episode requiring plasma infusion, more frequent recurrences and prescription of fresh frozen plasma prophylaxis. At receiver operating characteristic curve analysis, activity levels of less than 2.74% and 1.61% were discriminative of age at first TTP episode requiring plasma infusion <18 years, annual rate of TTP episodes >1, and use of prophylaxis. Mutations affecting the highly-conserved N-terminal domains of the protein were associated with lower residual ADAMTS13 activity and more severe phenotype in an allelic-dose dependent manner. Our results show that residual ADAMTS13 activity correlates with the severity of clinical phenotype in congenital TTP and provide insights into genotype-phenotype correlations.File | Dimensione | Formato | |
---|---|---|---|
440.full.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
296.67 kB
Formato
Adobe PDF
|
296.67 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.